Depression constitutes a widespread condition observed in elderly patients. Recently, it was found that several drugs employed in therapies against depression stimulate hippocampal neurogenesis in young rodents and nonhuman primates. As the rate of neurogenesis is dramatically reduced during ageing, we examined the influences of ageing on neurogenic actions of antidepressants. We tested the impact of fluoxetine, a broadly used antidepressant, on hippocampal neurogenesis in mice of three different age groups (100, 200 and over 400 days of age). Proliferation and survival rate of newly generated cells, as well as the percentage of cells that acquired a neuronal phenotype were analyzed in the hippocampus of mice that received fluoxetine daily in a chronic manner. Surprisingly, the action of fluoxetine on neurogenesis was decreasing as a function of age and was only significant in young animals. Hence, fluoxetine increased survival and the frequency of neuronal marker expression in newly generated cells of the hippocampus in the young adult group (that is 100 days of age) only. No significant effects on neurogenesis could be detected in fluoxetine-treated adult and elderly mice (200 and over 400 days of age). The data indicate that the action of fluoxetine on neurogenesis is highly dependent on the age of the treated individual. Although the function of neurogenesis in the clinical manifestation of depression is currently a matter of speculation, this study clearly shows that the therapeutic effects of antidepressants in elderly patients are not mediated by neurogenesis modulation.
Introduction
The formation of new neurons in the two neurogenic regions of the adult mammalian brain, that is the hippocampal dentate gyrus and the subventricular zone/olfactory bulb system, is a highly dynamic process. Of the numerous molecular and environmental factors that act on neurogenesis, ageing is by far the strongest modulator known. In rodents, neurogenesis declines dramatically with age. [1] [2] [3] [4] Thus, the number of proliferating cells in the hippocampal dentate gyrus decreases about 30-fold between the age of 60 and 540 days in rodents. 2 As a consequence of this reduced cell proliferation, only few new neurons are generated in aged individuals as compared to their young counterparts.
1,2,4-6 A recent study using magnetic resonance spectroscopy (MRS) indicated that a similar decline of neurogenesis occurs in the adult human hippocampus. 7, 8 Even though the overall number of new neurons generated in the aged brain is reduced, the electrophysiological and the functional properties of young neurons generated in the aged brain are nevertheless identical to those generated in young brains. 9 This further highlights the potential usefulness of neurogenesis modulation as part of therapeutic interventions in age-related diseases. 9 The age-related decline of neurogenesis has been associated with functional deficits in learning, memory and cognition. 10, 11 In addition, ageing correlates with higher prevalence of depression, as comorbid illnesses which are more common in the elderly increase the risk of major depression. 12, 13 Although the causative link between neurogenesis and the development of depression remains to be established, it is tempting to speculate on a contribution of declining rates of neurogenesis to the etiology of depression. Previous investigations reported a significant association between the clinical presentation of a depressive phenotype in patients and a substantial volume loss in the hippocampus detected by MR imaging. [14] [15] [16] [17] The reduction in hippocampal volume, however, predicts severity of depression only in younger adults and not in elderly individuals. 17 The most compelling evidences linking neurogenesis and depression were derived from preclinical experiments using animal models of stress, an environmental factor that strongly promotes depression and inhibits neurogenesis, 18, 19 for review see. 20 The inhibitory effects of stress on neurogenesis are mediated by adrenal gland-derived glucocorticoids. Moreover, a surplus of cortisol has been shown to downregulate neurogenesis in the dentate gyrus of adult rats and removal of the adrenal gland can partially counteract the age-related neurogenesis decline. [21] [22] [23] [24] Conversely, administration of antidepressants has been reported to promote neurogenesis in animal models. [25] [26] [27] [28] [29] Hence, chronic administration of different classes of antidepressant drugs was found to increase cell proliferation and neurogenesis in the subgranular zone of the dentate gyrus. 26 In this respect, fluoxetine, a serotonin-specific reuptake inhibitor, has been studied extensively. The exact mechanisms by which fluoxetine could promote neurogenesis is not yet clarified. However, chronic administration of fluoxetine for more then 14 days is required in animal models before an increase in cell proliferation can be detected. 26 This lag period correlates well with delays observed in patients before antidepressant treatment starts to be efficient. 30 Taken together, these observations suggest a link between increased neurogenesis and antidepressant activity.
Surprisingly, up to now the impact of ageing on the capacity of fluoxetine to promote neurogenesis has not been addressed. At least three scenarios might be envisaged. Considering that levels of neurogenesis are already high in younger as compared to aged individuals, younger brains might already use most of their neurogenic resources available. Therefore, antidepressants would dispose of larger reserves and be more potent to increase neurogenesis in the hippocampus of aged brains. Alternatively, as mentioned above, the aged brain milieu is inhospitable to neurogenesis and therefore, antidepressant treatment will stimulate neurogenesis more efficiently in young individuals. Finally, antidepressant activity on neurogenesis may be age independent.
This report addresses the impact of the antidepressant fluoxetine on neurogenesis as a function of age in mouse. The analysis of the individual component of net neurogenesis, that is cell proliferation, cell survival and neuronal differentiation, reveals that fluoxetine significantly promotes neurogenesis only in the youngest group of animals analyzed. As antidepressants can efficiently relief elderly individuals from depression-associated symptoms, our study further substantiates evidences that antidepressant action of compounds such as fluoxetine is not exclusively dependent on their neurogenic activities.
Materials and methods

Animals
Experiments were performed in conformity with the European Community Council Directive (86/609/EEC) and were approved by a national animal health commission. The experiments described in this report were performed on male C57BL/6 mice divided into three age groups at the beginning of the experiment: 100-day-old mice, 200-day-old and over 400 day-old (average 550-day old±72 days), n = 4-6 per group. These three time points correspond to the beginning, middle and late adulthood and did not encompassed adolescence or senescence. In human, these three history stages would roughly correspond to 20, 35 and 60 years of age. 31 Fluoxetine and BrdU injections Fluoxetine (Sigma, Taufkirchen, Germany) was dissolved in sterile phosphate-buffered saline (PBS) pH 7.4 and administrated i.p. daily at 10 mg kg À1 of body weight for the whole length of the experiment. In mice, this dosage has been reported to yield fluoxetine serum levels, which are comparable to those observed in patients receiving fluoxetine as antidepressant medication. 32, 33 Control animals received volume-matched injections of PBS. For the analysis of cell proliferation, mice received a single injection of BrdU at 200 mg kg À1 of body weight on day 28 and 2 h later mice were perfused under deep anesthesia with a pH 7.4 phosphate-buffered 4% paraformaldehyde solution. For analysis of cell survival and differentiation, mice received an injection of BrdU at 50 mg kg À1 of body weight on day 28, 29, 30 and 31 and were perfused on day 43.
Histology
Following transcardial perfusion with 4% paraformaldehyde, brains were removed and further postfixed overnight in pH 7.4 phosphate-buffered 4% paraformaldehyde solution at 4 1C. Brains were thereafter cryoprotected in a 30% sucrose 0.1 M sodium phosphate pH 7.4 solution and cut sagittal using a sliding microtome into 40 mm thick sections. Sections were stored in 25% glycerol, 25% ethylene glycol, 0.1 M sodium phosphate solution at À20 1C. Procedures for immunodetection were previously described. 34 The following primary antibodies were used: rat anti-BrdU 1/500 (Harlan Sera-Lab, Loughborough, UK), goat anti-DCX C18 1/250 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-GFAP 1/1000 (Dako, Glostrup, Denmark), mouse antirat nestin 1/200 (BD Biosciences, Pharmingen, San Diego, CA, USA), mouse anti-NeuN 1/500 (Chemicon, Temecula, CA, USA) and mouse anti-PCNA 1/1000 (Santa Cruz Biotechnology). Diaminobenzidine (DAB) stainings were obtained using the Vectastain Elite ABC-kit (Vector Laboratories, Burlingame, CA, USA) and DAB-stained sections were dehydrated and mounted in NeoMount (Merck, Darmstadt, Germany). Alternatively, primary antibodies were detected using Alexa-Fluor-conjugated secondary antibodies (Invitrogen, Molecular Probes, Karlsruhe, Germany) and sections were mounted in Prolong Gold (Invitrogen).
TdT-mediated dUTP nick end labeling (TUNEL) staining was performed using the ApopTag in situ Apoptosis Detection kit (Chemicon, Temecula, CA, USA) in a modified protocol previously described. 35 Microscopy and stereology Estimation of the total number of BrdU-or proliferating cell nuclear antigen (PCNA)-labeled cells in the dorsal dentate gyrus was performed using stereological techniques and the support of the StereoInvestigator software (MicroBrightField, Colchester, VT, USA) as described previously. 9 Representative random sagittal series representing either 1/5 or 2/5 of one brain hemisphere were analyzed. Only sections showing separated dorsal and ventral dentate gyrus were analyzed. The volume of the dorsal dentate gyrus was estimated by tracing the area on each analyzed section. Number of BrdU-or PCNA-labeled cells was estimated by counting every label cells within the traces.
Analysis of cell differentiation was investigated by the detection of the different cell-type markers in BrdU-labeled cells using a Leica TCS-NT laser confocal microscope. In the 100-and 200-day-old groups, 50 BrdU-labeled cells were analyzed for each marker. In the over 400-day-old group, due to the low level of neurogenesis, every BrdU-labeled cell detected was examined, however the total number of counted cells remained below 50.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 4.0 software (GraphPad Software, San Diego, CA, USA). Statistical significant difference at the t-test was assumed for P < 0.05. Values are expressed as average ± s.d.
Results
Chronic fluoxetine treatment does not affect hippocampal cell proliferation
The impact of 4 weeks of chronic fluoxetine treatment on the proliferation of neural precursors was first analyzed in mice of 100 days of age at the beginning of treatments. To this end, a single injection of BrdU to label all proliferating cells was performed 2 h before perfusion. Stereological quantification of BrdUlabeled cells revealed no significant difference between the mice that were treated with fluoxetine and those that received the vehicle only ( Figure 1 ; Table 1 ). Also, volumetric measurement revealed no significant differences in the volume of the dentate gyrus between the two experimental groups (data not shown).
To rule out possible interaction of chronic fluoxetine treatment with the biodistribution or availability of BrdU to proliferating cells, we analyzed the proliferation of neural precursors in the dentate gyrus using PCNA, a marker detected in the nucleus of proliferating cells. For this experiment, three groups of mice were enrolled that were either 100 days, 200 days or > 400 days of age at the beginning of a 6 weeks fluoxetine or vehicle treatment. In accordance with the proliferation measurements obtained using BrdU, no significant differences in cell proliferation between the fluoxetine-treated and the vehicle-treated mice could be detected in the dentate gyrus in any of the three age groups. Again, volumetric measurements on the dentate gyrus showed no significant differences between fluoxetine and vehicle injected animals (data not shown).
Chronic antidepressant treatment promotes survival of newly generated cells in young animals To address the possible impact of chronic fluoxetine treatment on the survival of newly generated cells in the dentate gyrus, BrdU-labeling was performed 2 weeks before perfusion (Figure 2 ). At 4 weeks before the first BrdU injection, mice started to receive fluoxetine or vehicle daily, and treatment was continued daily until perfusion. Hence, mice were maintained under chronic fluoxetine treatment for the whole length of the experiment.
The number of surviving newly generated cells was determined by stereological analyses of BrdU-labeled cells in the dorsal dentate gyrus in each of the three age groups. In the 100-day-old group, chronic fluoxetine treatment increased by 35% the number of BrdU-labeled cells detected in the dentate gyrus as compared to vehicle treatment ( Figure 2 ; Table 1 ). In contrast, no significant differences could be documented between the antidepressant and vehicletreated animals of the 200-day-old and the > 400-day-old groups. Similarly, TUNEL staining revealed no overt differences in any age groups in the number of apoptotic profiles present in the dentate gyrus of fluoxetine-treated as compared to vehicle-treated mice (Figure 2 ).
Chronic fluoxetine treatment promotes neuronal fate
The fate of newly generated cells under chronic fluoxetine treatment was also investigated by immunohistochemistry 2 weeks after BrdU labeling ( Figure 3 ; Table 2 ). Using cell-type-specific markers, we classified the BrdU-positive cells as neuronal cells if they expressed doublecortin (DCX, marker for immature neurons) or NeuN (marker for mature neurons). We classified the newly generated cells as astrocytes if they expressed glial fibrillary acidic protein (GFAP) or as multipotent precursors if they expressed nestin.
In the 100-day-old group, antidepressant treatment significantly increased the percentages of cells expressing neuronal markers (DCX and NeuN) 2 weeks after BrdU labeling. Whereas in vehicle-treated animals the percentage of BrdU-labeled neuronal cells was approximately 65.7 ± 12.3%, in the fluoxetine-treated animals, 85.3±11.3% of the newly generated cells expressed a neuronal marker. This neuronal gain was mainly resulting from an increase in the number of BrdU-labeled cells expressing NeuN, the marker for mature neurons, hence suggesting that chronic fluoxetine also influenced the maturation of newly generated cells.
In consequence, this gain in neuronal markers expression upon fluoxetine treatment further potentiated the effects of improved survival. Therefore, a robust increase in the net number of new neurons could be detected in the fluoxetine-treated mice of the 100-day-old group with 269±41 neuronal BrdUlabeled cells, as compared to 154 ± 30 in the vehicletreated animals. This represents an increase in net neurogenesis of 75% in the 100-day-old mouse group in response to chronic fluoxetine treatment.
In contrast, in the 200-day-old and > 400-day-old mouse groups, chronic fluoxetine administration did not significantly change percentages of cells expres- sing any of two neuronal markers DCX and NeuN ( Figure 3 ; Table 2 ). Similarly, the number of newly generated cells expressing GFAP or nestin was not significantly influenced by the chronic administration of fluoxetine regardless of the age group. In the 200-day-old and > 400-day-old groups however, the very low number of BrdU-labeled cells expressing these markers precluded statistical analysis.
Discussion
This report addresses the impact of ageing on the neurogenic effects of the antidepressant fluoxetine. Mice of three different groups of age received fluoxetine daily in a dosage leading to clinically relevant plasma concentrations over a long period of time to mimic chronic treatments administered to human patients. 32, 33 In young animals, we could confirm that fluoxetine promotes neurogenesis, as a result of an enhancement of survival of newly generated cells and a cell fate shift towards neuronal phenotypes. Fluoxetine, however, neither enhanced the proliferation rate of progenitors in the hippocampus of young animals nor in old animals.
To date, reported effects of fluoxetine on neurogenesis have been somewhat contradictory. Hence, a number of studies have demonstrated that fluoxetine stimulates cell proliferation in the rodent hippocampus [26] [27] [28] [29] 36, 37 and suggested that neurogenesis is required for the antidepressive effects of fluoxetine. 29, 38 Our study, however, substantiated more recent findings suggesting that stimulation of neurogenesis is not the sole mechanism of action of antidepressants. For example, it was recently demonstrated that fluoxetine neither stimulated cell proliferation nor neurogenesis in adult Balb/cJ mice, although behavioral effects were obtained. 39, 40 Furthermore, fluoxetine treatments (5 mg kg
À1
) of rats of different ages did not lead to an increase in hippocampal cell proliferation or survival. 41 In the later study however, only proliferation was assessed under ongoing chronic fluoxetine treatment.
Our findings in young animals are also in agreement with an in vitro study revealing that fluoxetine promoted survival and neuronal differentiation of progenitors in vitro, which correlated with an upregulation of Bcl-2 expression. 42 An strong upregulation of neurogenesis in association with an upregulation of Bcl-2 expression in the dentate gyrus was measured as well in nonhuman primates receiving electroconvulsive therapy (ECT), another potent therapeutic intervention used against depression. 43 Therefore, an increase of Bcl-2 expression levels might be a major component of the antidepressant activity. Increase in Bcl-2 antiapoptotic activity may indirectly support higher levels of neurogenesis in return, as higher Figure 2 Chronic antidepressant treatment promotes survival of newly generated cells in young animals. The number of BrdU-labeled cells remaining in the dentate gyrus of vehicle and fluoxetine-treated animals was assessed 2 weeks following BrdU administration in the (a) 100 days group, (b) 200 days group and (c) > 400 days group. Only the 100 days group showed a significant increase in the survival upon fluoxetine treatment (P < 0.05). (d) TdT-mediated dUTP nick end labeling (TUNEL) staining on the dentate gyrus of a fluoxetine-or vehicle-treated mice revealed no significant difference in the level of apoptosis. A representative micrograph shows two TUNEL-positive profiles (arrowhead), one of which can be seen at higher magnification in the inset. Scale bar 150 mm.
Bcl-2 expression has been previously demonstrated to improve survival of neuronal precursors during their phase of maturation and integration, leading to higher net neurogenesis rate. 44 Species and strain differences might be at the origin of discrepancies in antidepressant proliferative responses. Other experimental features such as the route and paradigm of drug administration, drug dosage, and the hormonal status of animals should also be taken into consideration. In this respect, the influence of fluoxetine on neurogenesis was shown to be significantly modulated by the diurnal rhythm in corticosterone. 45 In the same way, a significant interindividual variation in response to antidepressant treatments has also been well documented in patients, bringing clinicians to develop intervention strategies addressing the nonresponsiveness of some individuals (for example see Alexopoulos et al. 46 ). In this respect, a comparative analysis of neurogenic and nonneurogenic brain regions altered by major depression in responsive versus nonresponsive patients could be very pivotal. From these observations could arise future patient-tailored antidepressant therapies involving, for example, a stronger stimulation of neurogenesis, through increased physical activity or ECT, and/or a combination of drugs modulating neurotransmission.
Strikingly, this study revealed a lack of neurogenesis promoting activity of fluoxetine in the adult (200 days) and elderly ( > 400 days) mice. Chronic treatment with fluoxetine did neither increase proliferation, nor survival, nor neuronal differentiation in the hippocampus of these animals. Hence, age constitutes a major regulator of fluoxetine activities on neurogenesis, a phenomenon that was neglected so far. Although the underlying mechanisms are currently unknown, various reasons for the lack of effects of fluoxetine on neurogenesis might be envisaged. For example, the fluoxetine treatment paradigm used might not be sufficient to compensate the age-related reduction of the serotonin levels observed in the elderly brain. Indeed, during ageing, serotonin levels decrease significantly in various brain regions of rats, including the hippocampus. 47 In addition, neuronal precursors and immature neurons in the elderly hippocampus might have lost the responsiveness to increases of serotonin levels and therefore, to fluoxetine. In this regards, it has been reported that serotonin binding sites are lost during ageing. 48 The correlation between ageing and serotonin signaling has also been substantiated by the premature ageing of brains from animals bearing a targeted disruption of the serotonin receptor 1b. 49 One might speculate about the existence of intrinsic differences in differentiation and survival capacities of newly generated neurons in aged brains as compared to young brains. However, some observations argue against this hypothesis. Indeed, ageing was reported to specifically affect the generation of new cells in the neurogenic regions, but ageing did not affect the neuronal differentiation or survival. 3 Moreover, the electrophysiological and thus functional parameters of newly generated immature neurons were found to be indistinguishable in aged and in young brains. 9 Nevertheless, regardless of the precursors' intrinsic potential, the number of newly generated neurons that can be accommodated within the aged brain could be restricted as a result of a limited availability of trophic factors. In this regard, levels of brain-derived neurotrophic growth factor (BDNF) within the rat hippocampus have been shown to decrease by approximately 50% between 120 and 360 days of age, 50 and hence BDNF may become gradually a limiting factor for neuronal integration and survival along ageing. Whether fluoxetine administration can increase the levels of BDNF within the hippocampus remains a matter of debate. [51] [52] [53] Ultimately, the elderly brain parenchyma might constitute an environment enriched in neurogenesis inhibitory molecules that exert a dominant effect over the neurogenesis-promoting effect of fluoxetine (for review see Drapeau and Nora Abrous 11 ). For example, the gradual increase in corticosteroids level during ageing has been implicated in age-related downregulation of neurogenesis. 54 Indeed, it was clearly demonstrated that corticosterone inhibits cell proliferation in the dentate gyrus. 22, 55 Moreover, a reduction of corticosterone levels obtained following adrenalectomy raised rates of neurogenesis in aged animals. 23, 56 Transforming growth factor-b (TGF-b) signaling is another pathway recently associated with reduced levels of neurogenesis during ageing and in neurodegenerative diseases. In this regard, we and others reported that intracerebroventricular infusions of TGF-b into the rat brain or overexpression of TGF-b in transgenic mice resulted in a marked downregulation of cell proliferation and neurogenesis in the hippocampus. 57, 58 Moreover, levels of TGF-b are known to be increasing in the brain along with ageing. 59, 60 Additional experiments targeting specifically the individual signaling systems are required to elucidate in the age-dependent loss of fluoxetine activities on neurogenesis.
In conclusion, this study reveals that the neurogenic action of antidepressant is decreasing during ageing. The function of neurogenesis in the clinical manifestation of depression is currently a matter of speculation. Owing the fact that antidepressant can efficiently relieve elderly individuals from depression-associated symptoms, our study further substantiated evidences that action of compounds such as fluoxetine does not solely depend on their activity on neurogenesis. 
